| Call for patient/clinician input open | 04-Jul-23 |
|---|---|
| Call for patient/clinician input closed | 25-Aug-23 |
| Submission received | 15-Aug-23 |
| Submission accepted | 29-Aug-23 |
| Review initiated | 30-Aug-23 |
| Clarification: - Submission temporarily suspended -Voluntarily withdrawn by the sponsor on 26 Sep 2023 | |
| Call for patient/clinician input open | July 04, 2023 |
|---|---|
| Call for patient/clinician input closed | August 25, 2023 |
| Clarification: - Patient input submission received from Canadian Cancer Society | |
| Submission received | August 15, 2023 |
| Submission accepted | August 29, 2023 |
| Review initiated | August 30, 2023 |
| Draft CADTH review report(s) provided to sponsor for comment | November 16, 2023 |
| Clarification: - Submission temporarily suspended - Additional information has been received and the temporary suspension of the review has been lifted | |
| Deadline for sponsors comments | December 06, 2023 |
| Clarification: - Voluntarily withdrawn by the sponsor on 19 February 2025 | |
| Call for patient/clinician input open | 30-Jun-23 |
|---|---|
| Call for patient/clinician input closed | 25-Aug-23 |
| Clarification: - No patient input submission received | |
| Submission received | 14-Aug-23 |
| Submission accepted | 30-Aug-23 |
| Review initiated | 31-Aug-23 |
| Clarification: - Submission was not accepted for review on 28 Aug 2023 | |
| Draft Canada's Drug Agency review report(s) provided to sponsor for comment | 24-Nov-23 |
| Deadline for sponsors comments | 05-Dec-23 |
| Canada's Drug Agency review report(s) and responses to comments provided to sponsor | 12-Jan-24 |
| Expert committee meeting (initial) | 24-Jan-24 |
| Draft recommendation issued to sponsor | 06-Feb-24 |
| Draft recommendation posted for stakeholder feedback | 15-Feb-24 |
| End of feedback period | 01-Mar-24 |
| Final recommendation issued to sponsor and drug plans | 18-Mar-24 |
| Final recommendation posted | 04-Apr-24 |
| Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s) | 02-Apr-24 |
| Canada's Drug Agency review report(s) posted | 25-Jul-24 |
Review Type: Rapid
Provisional Funding Algorithm |
|
|---|---|
| Draft Report Posted: | June 22, 2023 |
| Stakeholder Feedback Deadline: | June 29, 2023 |
| Final Report Posted : | July 27, 2023 |
See Pharmaceutical Reviews Update ― Issue 39 for important news and information regarding the Canada's Drug Agency drug review programs. Highlights from this issue include:
1. Updated Procedures for Streamlined Drug Class Reviews
| Call for patient/clinician input open | 14-Jun-23 |
|---|---|
| Call for patient/clinician input closed | 04-Aug-23 |
| Clarification: - Patient input submission received from the Leukemia & Lymphoma Society of Canada | |
| Submission received | 26-Jul-23 |
| Submission accepted | 10-Aug-23 |
| Review initiated | 11-Aug-23 |
| Draft CADTH review report(s) provided to sponsor for comment | 02-Nov-23 |
| Deadline for sponsors comments | 14-Nov-23 |
| CADTH review report(s) and responses to comments provided to sponsor | 08-Dec-23 |
| Expert committee meeting (initial) | 20-Dec-23 |
| Draft recommendation issued to sponsor | 10-Jan-24 |
| Draft recommendation posted for stakeholder feedback | 18-Jan-24 |
| End of feedback period | 02-Feb-24 |
| Final recommendation posted | 05-Mar-24 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | 01-Mar-24 |
| CADTH review report(s) posted | 01-May-24 |
| Call for patient/clinician input open | 13-Jun-23 |
|---|---|
| Call for patient/clinician input closed | 04-Aug-23 |
| Clarification: - Patient input submission received from the Lipodystrophy Canada Foundation | |
| Submission received | 25-Jul-23 |
| Submission accepted | 09-Aug-23 |
| Review initiated | 10-Aug-23 |
| Draft Canada's Drug Agency review report(s) provided to sponsor for comment | 26-Oct-23 |
| Deadline for sponsors comments | 06-Nov-23 |
| Canada's Drug Agency review report(s) and responses to comments provided to sponsor | 08-Dec-23 |
| Expert committee meeting (initial) | 20-Dec-23 |
| Draft recommendation issued to sponsor | 22-Jan-24 |
| Draft recommendation posted for stakeholder feedback | 01-Feb-24 |
| End of feedback period | 15-Feb-24 |
| Clarification: - Reconsideration: major revisions requested by sponsor | |
| Expert committee meeting | 24-Apr-24 |
| Final recommendation issued to sponsor and drug plans | 09-May-24 |
| Final recommendation posted | 28-May-24 |
| Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s) | 24-May-24 |
| Clarification: - Extension requested by sponsor | |
| Canada's Drug Agency review report(s) posted | 10-Oct-24 |
See Pharmaceutical Reviews Update ― Issue 38 for important news and information regarding the Canada's Drug Agency drug review programs. Highlights from this issue include:
| Call for patient/clinician input open | June 06, 2023 |
|---|---|
| Call for patient/clinician input closed | July 28, 2023 |
| Clarification: - Patient input submission received from Lymphoma Canada | |
| Submission received | July 18, 2023 |
| Submission accepted | August 01, 2023 |
| Review initiated | August 02, 2023 |
| Draft Canada's Drug Agency review report(s) provided to sponsor for comment | October 19, 2023 |
| Deadline for sponsors comments | October 30, 2023 |
| Canada's Drug Agency review report(s) and responses to comments provided to sponsor | November 24, 2023 |
| Expert committee meeting (initial) | December 06, 2023 |
| Draft recommendation issued to sponsor | December 20, 2023 |
| Draft recommendation posted for stakeholder feedback | January 04, 2024 |
| End of feedback period | January 18, 2024 |
| Final recommendation issued to sponsor and drug plans | February 02, 2024 |
| Final recommendation posted | February 21, 2024 |
| Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s) | February 16, 2024 |
| Canada's Drug Agency review report(s) posted | April 22, 2024 |
| Call for patient/clinician input open | June 06, 2023 |
|---|---|
| Call for patient/clinician input closed | July 28, 2023 |
| Clarification: - Patient input submission received from Breast Cancer Canada and McPeak-Sirois Group for Clinical Research in Breast Cancer Research, Canadian Breast Cancer Network and Rethink Breast Cancer | |
| Submission received | July 18, 2023 |
| Submission accepted | August 01, 2023 |
| Review initiated | August 02, 2023 |
| Draft CADTH review report(s) provided to sponsor for comment | October 19, 2023 |
| Deadline for sponsors comments | October 30, 2023 |
| CADTH review report(s) and responses to comments provided to sponsor | November 24, 2023 |
| Expert committee meeting (initial) | December 06, 2023 |
| Draft recommendation issued to sponsor | December 19, 2023 |
| Draft recommendation posted for stakeholder feedback | January 04, 2024 |
| End of feedback period | January 18, 2024 |
| Final recommendation issued to sponsor and drug plans | February 01, 2024 |
| Final recommendation posted | February 20, 2024 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | February 15, 2024 |
| CADTH review report(s) posted | April 25, 2024 |